Yarrow Bioscience, Inc. (YARW)

♥ 639 Thanks from members

Yarrow Bioscience, Inc. (YARW) trades around $42 with a $57-$58 consensus price target following its transformative reverse merger with VYNE Therapeutics and a $200 million capital raise to advance autoimmune thyroid disease clinical trials.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Yarrow Bioscience Team Leadership: Biotech Executive Leadership Holder: Life Science Venture Funds Yarrow Pipeline Therapeutics #YARW #Yarrow Bioscience #Biotech Startup #Metabolic Disease #NASDAQ